Search for a trial

An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with well-differentiated advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or poorly-differentiated gasteroenteropancreatic neuroendocrine carcinoma (GEP-NEC) who have progressed on prior treatment (CPDR001E2201)

Primary: To estimate the antitumor activity (assessed as overall response rate) of PDR001 as a single agent in patients with non-functional neuro-endocrine tumors (NET).Secondary: To estimate efficacy (duration of response) of PDR001. Safety and…